Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study
| dc.rights.license | open | en_US |
| dc.contributor.author | ALBIGES, Laurence | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | BELLERA, Carine | |
| dc.contributor.author | BRANCHOUX, Sebastien | |
| dc.contributor.author | ARNAUD, Mickael | |
| dc.contributor.author | GOUVERNEUR, Amandine | |
| dc.contributor.author | NERE, Sonia | |
| dc.contributor.author | GAUDIN, Anne-Francoise | |
| dc.contributor.author | DURAND-ZALESKI, Isabelle | |
| dc.contributor.author | NEGRIER, Sylvie | |
| dc.date.accessioned | 2024-05-15T11:31:53Z | |
| dc.date.available | 2024-05-15T11:31:53Z | |
| dc.date.issued | 2023-11-24 | |
| dc.identifier.issn | 1938-0682 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/199872 | |
| dc.description.abstractEn | BACKGROUND: Treatment landscape for advanced renal cell carcinoma (aRCC) has evolved quickly and few data about the real-world treatment patterns are available. This study aimed at describing the real-world treatment patterns and effectiveness of all systemic treatments available for aRCC in first and second-line treatment. MATERIALS AND METHODS: A cohort of patients initiating a first-line systemic treatment for aRCC in 2016 was extracted from the French nationwide healthcare insurance system database (SNDS). The first-line treatment initiation date constituted the index date and patients were followed until death, loss to follow-up, or December 31, 2019, whichever occurred first. aRCC was identified using hospital diagnosis, long-term disease, or renal biopsy before index date. All analyses were performed for first and second-line treatment. Overall survival (OS) and time-to-next treatment or death (TNT-D) were estimated using Kaplan-Meier approach. RESULTS: In 2016, 1629 patients initiated a first-line treatment for aRCC. Most of them were male (75.9%) and the median age was 67 years. Most of patients (91.7%) had received a tyrosine kinase inhibitor as first-line treatment, mainly sunitinib (64.4%), and 53.5% received a second-line, among which 43.7% nivolumab. Median OS (95% confidence interval [CI]) was 20.7 (95% CI:18.2-22.4) months from first-line treatment initiation and 15.4 (13.9-17.5) months from second-line treatment initiation. Median TNT-D were respectively 9.3 (9.7-12.1) months and 6.9 (5.9-7.7) months. CONCLUSION: This study highlights the limited survival of aRCC patients These results provide a valuable baseline and highlight the need for innovation, such as immune checkpoint inhibitor-based combinations that have recently became first-line standard of care. | |
| dc.language.iso | EN | en_US |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | * |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | * |
| dc.subject.en | Carcinoma | |
| dc.subject.en | Renal cell | |
| dc.subject.en | Real-world outcomes | |
| dc.subject.en | Treatment patterns | |
| dc.title.en | Real-World Treatment Patterns and Effectiveness of Patients With Advanced Renal Cell Carcinoma: A Nationwide Observational Study | |
| dc.title.alternative | Clin Genitourin Cancer | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1016/j.clgc.2023.11.012 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 38105152 | en_US |
| bordeaux.journal | Clinical Genitourinary Cancer | en_US |
| bordeaux.page | 295-304 | en_US |
| bordeaux.volume | 22 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - UMR 1219 | en_US |
| bordeaux.issue | 2 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.institution | INSERM | en_US |
| bordeaux.team | EPICENE_BPH | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-04576098 | |
| hal.version | 1 | |
| hal.date.transferred | 2024-05-15T11:31:55Z | |
| hal.popular | non | en_US |
| hal.audience | Internationale | en_US |
| hal.export | true | |
| dc.rights.cc | Pas de Licence CC | en_US |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical%20Genitourinary%20Cancer&rft.date=2023-11-24&rft.volume=22&rft.issue=2&rft.spage=295-304&rft.epage=295-304&rft.eissn=1938-0682&rft.issn=1938-0682&rft.au=ALBIGES,%20Laurence&BELLERA,%20Carine&BRANCHOUX,%20Sebastien&ARNAUD,%20Mickael&GOUVERNEUR,%20Amandine&rft.genre=article |
